Kuramoto Takafumi, Sakuraba Koji, Kai Kazuhiro, Terada Kazumasa, Kobara Nobuo, Bekki Hirofumi, Fukushi Jun-Ichi
Clinical Research Center, NHO Kyushu Medical Center, Jigyohama 1-8-1, Chuo-Ku, Fukuoka, 810-8563, Japan.
Department of Orthopaedic Surgery and Rheumatology, NHO Kyushu Medical Center, Jigyohama 1-8-1, Chuo-Ku, Fukuoka, 810-8563, Japan.
Arthritis Res Ther. 2025 Jul 1;27(1):131. doi: 10.1186/s13075-025-03593-w.
The effect of biologics on cervical spine lesions (CSLs) and vital prognosis in patients with rheumatoid arthritis (RA) remains unclear. This study investigated the risk factors for a poor vital prognosis in patients with RA requiring primary cervical spine surgery for CSLs.
We retrospectively investigated 139 patients with RA who underwent primary cervical spine surgery between January 2001 and December 2020. The vital prognosis was calculated using the Kaplan-Meier method. Patient data were collected from medical records to analyse the risk factors for vital prognosis using univariate and multivariate Cox regression analyses.
The vital prognosis was 62.7% at 10 years according to the Kaplan-Meier method. In univariate analysis, advanced age, lower serum albumin levels, high-dose prednisolone administration, non-use of methotrexate, and subaxial subluxation (SAS) comorbidity were significantly associated with a high risk of mortality. In multivariate analysis, advanced age, lower serum albumin levels, high-dose prednisolone administration, and SAS comorbidity were identified as risk factors for a poor vital prognosis.
SAS comorbidity, high-dose prednisolone administration, lower serum albumin levels, and advanced age exacerbate the vital prognosis in patients with RA requiring primary cervical spine surgery. Strict disease control aimed at preventing CSL progression to SAS by maintaining the nutritional status and without using steroids is necessary to improve the vital prognosis of patients with RA.
生物制剂对类风湿关节炎(RA)患者颈椎病变(CSL)及生存预后的影响尚不清楚。本研究调查了因CSL需行一期颈椎手术的RA患者生存预后不良的危险因素。
我们回顾性调查了2001年1月至2020年12月期间接受一期颈椎手术的139例RA患者。采用Kaplan-Meier法计算生存预后。从病历中收集患者数据,采用单因素和多因素Cox回归分析来分析生存预后的危险因素。
根据Kaplan-Meier法,10年时的生存预后为62.7%。单因素分析中,高龄、血清白蛋白水平较低、高剂量泼尼松龙给药、未使用甲氨蝶呤以及下颈椎半脱位(SAS)合并症与高死亡风险显著相关。多因素分析中,高龄、血清白蛋白水平较低、高剂量泼尼松龙给药和SAS合并症被确定为生存预后不良的危险因素。
SAS合并症、高剂量泼尼松龙给药、血清白蛋白水平较低和高龄会使因CSL需行一期颈椎手术的RA患者的生存预后恶化。通过维持营养状况且不使用类固醇来严格控制疾病以防止CSL进展为SAS,对于改善RA患者的生存预后是必要的。